Biotechnology industry association elects new board – 22nd Annual General Meeting of BIO Deutschland e. V.
Biotechnology industry association elects new board – 22nd Annual General Meeting of BIO Deutschland e. V.
Berlin (September 18, 2025) – The biotechnology industry association, BIO Deutschland e. V., elected a new board for the next two years during its 22nd Annual General Meeting in Berlin.
The ten members of the BIO Deutschland board represent different areas of the innovative biotechnology industry.
The following were re-elected:
- Prof. Dr. Kathrin Sabine Adlkofer, Chief Executive Officer and founder of Cellbox Solutions GmbH, Lübeck
- Norbert Hentschel, Commercial Managing Director of Miltenyi Biotec B.V. & Co. KG, Bergisch-Gladbach
- Dr. Klaus Maleck, Chief Financial Officer, ITM SE, Munich
- Oliver Schacht, PhD, Oliver Schacht, PhD, Managing Director of Life Science Nord Management GmbH, Hamburg
- Roland Sackers, Chief Financial Officer and Managing Director of QIAGEN N.V., Hilden
- Dr. Sylvia Wojczewski, Chief Executive Officer of BioSpring GmbH, Frankfurt am Main
Newly elected to the Executive Board:
- Dr. Hubert Birner, Managing Partner of TVM Capital GmbH and TVM Life Science Management GmbH, Munich
- Peter Mitterhofer, General Manager Germany of BioNTech Europe GmbH, Mainz, Berlin
- Dr. Dominik Schumacher, CEO of Tubulis GmbH, Planegg
- Raffael Wohlgensinger, CEO of Formo Bio GmbH, Berlin, Frankfurt am Main
Following the general meeting, the new Executive Board unanimously elected Roland Sackers as its new Chairman. Norbert Hentschel was re-elected as Treasurer.
“I am delighted to have the trust of the members and my colleagues on the Executive Board,” said Roland Sackers after his election. “A lot has changed for the biotechnology industry in recent months. The coalition agreement and the German government's high-tech agenda clearly recognize for the first time the importance of biotechnology as a key technology for Germany as a business location. This is right, important, and encouraging and we can build on it. On the other hand, global tariff policy presents our industry with challenges whose effects cannot yet be fully predicted,” Sackers continued, emphasizing: “We will work hard to further shape the framework conditions for our industry and promote Germany as a biotech location. In this context, I would like to express my special thanks to Oliver Schacht, who, as chairman of the board for the past six years, has made a decisive contribution to anchoring our concerns in politics and the public sphere and providing important impetus for the development of the association.”
At the general meeting, the association's management also presented a comprehensive report and briefly highlighted the main activities of the past twelve months.
385 words/2544 characters incl. spaces
Further information on the Executive Board can be found here: www.biodeutschland.org/en/board.html
About BIO Deutschland:
BIO Deutschland e. V. is an independent biotechnology organization. The association represents the interests of its members at national, European, and global level. Biotechnology translates biology into industrial applications. It has already demonstrated widely visible benefits in medicine, for example. Innovative bio-based economic systems can enable Germany and Europe to achieve long-term sovereignty and prosperity. The association's network is interdisciplinary and unique. Its members conduct research, development, production, and marketing on a global scale. BIO Deutschland is a strong community. It is committed to diversity, openness, and equal opportunities, and is dedicated to the free democratic basic order. Roland Sackers is the Chairman of the Board of BIO Deutschland.
Further information is available at; www.biodeutschland.org
BIO Deutschland's supporting members and industry partners are:
AGC Biologics, Avia, Baker Tilly, Bayer, BioSpring, Boehringer Ingelheim, BüchnerBarella, Citeline, CMS Hasche Sigle, Deutsche Bank, Ernst & Young, Evotec, IDT Biologika, ITM, KPMG, Lonza, Miltenyi Biotec, Novartis, PricewaterhouseCoopers, QIAGEN, Rentschler Biopharma, Roche Diagnostics, Sanofi Aventis Deutschland, Thermo Fisher Scientific, Vertex Pharmaceuticals, Vibalogics, ZETA.
Contact:
BIO Deutschland e. V.
Dr. Claudia Englbrecht
Schützenstraße 6a
10117 Berlin
Tel.: +49 30 2332 164-32
Mobile: +49 151 14067326
E-Mail: englbrecht@biodeutschland.org
Reprint free of charge, sample requested.
